Buy Shalby; target of Rs 180: ICICI Direct

ICICI Direct's research report on Shalby

Started by renowned orthopaedic surgeon Dr Vikram Shah, Shalby is a multi-specialty hospitals chain with expertise in joint replacement. Revenue-wise breakup Q2FY23: arthroplasty:39%, critical care & general medicine: 10%, cardiac science: 10%, orthopaedic: 9%, oncology:11%, neurology 5%, nephrology:5%, others:13% • Shalby registered a blended ARPOB of Rs 33439 and ALOS of 3.90 days (without day care procedures) in Q2FY23 • Acquisition of US based Consensus to diversify into related implant business besides supporting arthroplasty and orthopaedic segments.

Outlook

We maintain BUY due to 1) judicious pan-India push banking on surgical expertise, 2) asset light model via franchisee drive and 3) implants likely to provide integration advantage and third party push in core markets. We value Shalby at Rs 180 based on SOTP valuation.

What is your view on Shalby?

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Shalby - 251022 - icici